Unraveling the therapeutic potential of the Hedgehog pathway in cancer

Nature Medicine

Volumn 19, Issue 11, 2013, Pages 1410-1422

  Amakye, Dereck ^a   Jagani, Zainab ^b   Dorsch, Marion ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c AGIOS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BEVACIZUMAB; BMS 833923; BORTEZOMIB; BUPARLISIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYTARABINE; DASATINIB; DAUNORUBICIN; DEXAMETHASONE; ERLOTINIB; ETOPOSIDE; GEMCITABINE; INC 424; JANUS KINASE INHIBITOR; LENALIDOMIDE; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; NILOTINIB; PF 04449913; RAPAMYCIN; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VISMODEGIB;

ACUTE GRANULOCYTIC LEUKEMIA; AGEUSIA; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BACKACHE; BREAST CANCER; CANCER STEM CELL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM CANCER; DROSOPHILA MELANOGASTER; DYSGEUSIA; ESOPHAGUS CANCER; FAINTNESS; FATIGUE; GASTROINTESTINAL HEMORRHAGE; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; LUNG SMALL CELL CANCER; LYMPHOCYTE COUNT; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCLE CRAMP; MUSCLE SPASM; MYALGIA; MYELOFIBROSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; REVIEW; SEIZURE; SENSORY NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; THROMBOEMBOLISM; THROMBOSIS; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UPREGULATION; VOMITING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; HEDGEHOG PROTEINS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; NEOPLASTIC STEM CELLS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84887512714     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3389     Document Type: Review

References (130)

1. Scales, S.J. & de Sauvage, F.J. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol. Sci. 30, 303-312 (2009).
2. La Fleur, L., Johansson, A.C. & Roberg, K.A. CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment. PLoS ONE 7, e44071 (2012).
3. McMahon, A.P., Ingham, P.W. & Tabin, C.J. Developmental roles and clinical significance of hedgehog signaling. Curr. Top. Dev. Biol. 53, 1-114 (2003).
4. Gailani, M.R. et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat. Genet. 14, 78-81 (1996).
5. Xie, J. et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391, 90-92 (1998).
6. Slade, I. et al. Heterogeneity of familial medulloblastoma and contribution of germline PTCH1 and SUFU mutations to sporadic medulloblastoma. Fam. Cancer 10, 337-342 (2011).
7. Raffel, C. et al. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 57, 842-845 (1997).
8. Reifenberger, J. et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 58, 1798-1803 (1998).
9. Taylor, M.D. et al. Mutations in SUFU predispose to medulloblastoma. Nat. Genet. 31, 306-310 (2002).
10. Rudin, C.M. Vismodegib. Clin. Cancer Res. 18, 3218-3222 (2012).
11. Amakye, D. The predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for Hedgehog pathway inhibitor therapy. Cancer Res. 72 (suppl. 1), abstract 4818 (2012).
12. Berlin, J. et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin. Cancer Res. 19, 258-267 (2013).
13. Kaye, S.B. et al. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin. Cancer Res. 18, 6509-6518 (2012).
14. Infinity Pharmaceuticals. Infinity reports update from phase 2 study of saridegib plus gemcitabine in patients with metastatic pancreatic cancer. News Releasehttp://phx.corporate-ir.net/phoenix.zhtml?c=121941&p= irol-newsArticle&ID=1653550 (27 January 2012).
15. Infinity Pharmaceuticals. Infinity stops phase 2 trials of saridegib in chondrosarcoma and myelofibrosis. Fierce Biotech: Press Release http://www.fiercebiotech.com/press-releases/infinity-stops-phase-2-trials- saridegib-chondrosarcoma-and-myelofibrosis (18 June 2012).
16. Nüsslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 287, 795-801 (1980).
17. Ingham, P.W. & McMahon, A.P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 15, 3059-3087 (2001).
18. van den Brink, G.R. Hedgehog signaling in development and homeostasis of the gastrointestinal tract. Physiol. Rev. 87, 1343-1375 (2007).
19. Varjosalo, M. & Taipale, J. Hedgehog: functions and mechanisms. Genes Dev. 22, 2454-2472 (2008).
20. Eggenschwiler, J.T. & Anderson, K.V. Cilia and developmental signaling. Annu. Rev. Cell Dev. Biol. 23, 345-373 (2007).
21. Wong, S.Y. & Reiter, J.F. The primary cilium at the crossroads of mammalian hedgehog signaling. Curr. Top. Dev. Biol. 85, 225-260 (2008).
22. Merchant, M. et al. Suppressor of fused regulates Gli activity through a dual binding mechanism. Mol. Cell Biol. 24, 8627-8641 (2004).
23. Kogerman, P. et al. Mammalian suppressor-of-fused modulates nuclear-cytoplasmic shuttling of Gli-1. Nat. Cell Biol. 1, 312-319 (1999).
24. Stone, D.M. et al. Characterization of the human suppressor of fused, a negative regulator of the zinc-finger transcription factor Gli. J. Cell Sci. 112, 4437-4448 (1999).
25. Hahn, H. et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996).
26. Gorlin, R.J. Nevoid basal cell carcinoma syndrome. Dermatol. Clin. 13, 113-125 (1995).
27. Sun, L.S., Li, X.F. & Li, T.J. PTCH1 and SMO gene alterations in keratocystic odontogenic tumors. J. Dent. Res. 87, 575-579 (2008).
28. Epstein, E.H. Basal cell carcinomas: attack of the hedgehog. Nat. Rev. Cancer 8, 743-754 (2008).
29. Vorechovsky, I. et al. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene 15, 361-366 (1997).
30. Barreto, D.C., Gomez, R.S., Bale, A.E., Boson, W.L. & De Marco, L. PTCH gene mutations in odontogenic keratocysts. J. Dent. Res. 79, 1418-1422 (2000).
31. Lam, C.W. et al. A frequent activated smoothened mutation in sporadic basal cell carcinomas. Oncogene 18, 833-836 (1999).
32. Brastianos, P.K. et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat. Genet. 45, 285-289 (2013).
33. Clark, V.E. et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 339, 1077-1080 (2013).
34. Mao, J. et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res. 66, 10171-10178 (2006).
35. Brugieres, L. et al. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J. Clin. Oncol. 30, 2087-2093 (2012).
36. Aavikko, M. et al. Loss of SUFU function in familial multiple meningioma. Am. J. Hum. Genet. 91, 520-526 (2012).
37. Jones, D.T. et al. Dissecting the genomic complexity underlying medulloblastoma. Nature 488, 100-105 (2012).
38. Parsons, D.W. et al. The genetic landscape of the childhood cancer medulloblastoma. Science 331, 435-439 (2011).
39. Pugh, T.J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106-110 (2012).
40. Corcoran, R.B. & Scott, M.P. A mouse model for medulloblastoma and basal cell nevus syndrome. J. Neurooncol. 53, 307-318 (2001).
41. Hahn, H. et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat. Med. 4, 619-622 (1998).
42. Wetmore, C., Eberhart, D.E. & Curran, T. The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res. 60, 2239-2246 (2000).
43. Kimura, H., Stephen, D., Joyner, A. & Curran, T. Gli1 is important for medulloblastoma formation in Ptc1+/? mice. Oncogene 24, 4026-4036 (2005).
44. Nilsson, M. et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc. Natl. Acad. Sci. USA 97, 3438-3443 (2000).
45. Sekulic, A. et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N. Engl. J. Med. 366, 2171-2179 (2012).
46. Tang, J.Y. et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N. Engl. J. Med. 366, 2180-2188 (2012).
47. Rubin, L.L. & de Sauvage, F.J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 5, 1026-1033 (2006).
48. Ng, J.M. & Curran, T. The Hedgehog's tale: developing strategies for targeting cancer. Nat. Rev. Cancer 11, 493-501 (2011).
49. Yauch, R.L. et al. A paracrine requirement for hedgehog signalling in cancer. Nature 455, 406-410 (2008).
50. Mills, L.D. et al. Loss of the transcription factor GLI1 identifies a signaling network in the tumor microenvironment mediating KRAS oncogene-induced transformation. J. Biol. Chem. 288, 11786-11794 (2013).
51. Tian, H. et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl. Acad. Sci. USA 106, 4254-4259 (2009).
52. Olive, K.P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
53. Chang, Q., Foltz, W.D., Chaudary, N., Hill, R.P. & Hedley, D.W. Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition. Int. J. Cancer 133, 225-234 (2013).
54. Dierks, C. et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat. Med. 13, 944-951 (2007).
55. Merchant, A.A. & Matsui, W. Targeting Hedgehog-a cancer stem cell pathway. Clin. Cancer Res. 16, 3130-3140 (2010).
56. Clevers, H. The cancer stem cell: premises, promises and challenges. Nat. Med. 17, 313-319 (2011).
57. Magee, J.A., Piskounova, E. & Morrison, S.J. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283-296 (2012).
58. Bar, E.E. et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 25, 2524-2533 (2007).
59. Feldmann, G. et al. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 7, 2725-2735 (2008).
60. Liu, S. et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 66, 6063-6071 (2006).
61. Jagani, Z., Dorsch, M. & Warmuth, M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 9, 3449-3456 (2010).
62. Blotta, S. et al. Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 120, 5002-5013 (2012).
63. Varnat, F. et al. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 1, 338-351 (2009).
64. Dierks, C. et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14, 238-249 (2008).
65. Zhao, C. et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 458, 776-779 (2009).
66. Aberger, F., Kern, D., Greil, R. & Hartmann, T.N. Canonical and noncanonical Hedgehog/GLI signaling in hematological malignancies. Vitam. Horm. 88, 25-54 (2012).
67. Karamboulas, C. & Ailles, L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim. Biophys. Acta 1830, 2481-2495 (2013).
68. Dennler, S. et al. Induction of sonic hedgehog mediators by transforming growth factor-?: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 67, 6981-6986 (2007).
69. Ji, Z., Mei, F.C., Xie, J. & Cheng, X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J. Biol. Chem. 282, 14048-14055 (2007).
70. Nolan-Stevaux, O. et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 23, 24-36 (2009).
71. Rajurkar, M. et al. The activity of Gli transcription factors is essential for Kras-induced pancreatic tumorigenesis. Proc. Natl. Acad. Sci. USA 109, E1038-E1047 (2012).
72. Riobó, N.A., Lu, K., Ai, X., Haines, G.M. & Emerson, C.P. Jr. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc. Natl. Acad. Sci. USA 103, 4505-4510 (2006).
73. Rao, G. et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23, 6156-6162 (2004).
74. Wang, Y. et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 21, 374-387 (2012).
75. Jagani, Z. et al. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat. Med. 16, 1429-1433 (2010).
76. Cooper, M.K., Porter, J.A., Young, K.E. & Beachy, P.A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280, 1603-1607 (1998).
77. Chen, J.K., Taipale, J., Cooper, M.K. & Beachy, P.A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16, 2743-2748 (2002).
78. Peukert, S. & Miller-Moslin, K. Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics. ChemMedChem 5, 500-512 (2010).
79. Geoerger, B. et al. A phase I/II study of LDE225, a Smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors. J. Clin. Oncol. 30 (suppl. 15), abstract 9519 (2012).
80. Jimeno, A. et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin. Cancer Res. 19, 2766-2774 (2013).
81. LoRusso, P.M. et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 17, 2502-2511 (2011).
82. Rudin, C.M. et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361, 1173-1178 (2009).
83. Siu, L.L. et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. J. Clin. Oncol. 28 (suppl. 15), abstract 2501 (2010).
84. Tawbi, H.A. et al. Phase I study of LDE225 in advanced solid tumors: updated analysis of safety, preliminary efficacy, and pharmacokinetic- pharmacodynamic correlation. J. Clin. Oncol. 29 (suppl.), abstract 3062 (2011).
85. Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92, 205-216 (2000).
86. Gajjar, A.J. et al. A prospective phase II study to determine the efficacy of GDC 0449 (vismodegib) in adults with recurrent medulloblastoma (MB): a Pediatric Brain Tumor Consortium study (PBTC 25B). J. Clin. Oncol. 31 (suppl.), abstract 2035 (2013).
87. Amakye, D. et al. Development of a five-gene Hedgehog signature as a patient preselection tool for Hedgehog pathway-targeted therapy in medulloblastoma. Neuro. Oncol. 15 (suppl. 1), abstract 0125 (2013).
88. Jamieson, C. et al. Phase 1 dose-escalation study of PF-04449913, an oral Hedgehog (Hh) inhibitor, in patients with select hematologic malignancies. 53rd ASH Annual Meeting and Exposition oral abstract 424 ?https://ash.confex.com/ ash/2011/webprogram/Paper38232.html? (2011).
89. Kimura, H., Ng, J.M. & Curran, T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 13, 249-260 (2008).
90. Wang, Y., Zhou, Z., Walsh, C.T. & McMahon, A.P. Selective translocation of intracellular Smoothened to the primary cilium in response to Hedgehog pathway modulation. Proc. Natl. Acad. Sci. USA 106, 2623-2628 (2009).
91. Wilson, C.W., Chen, M.H. & Chuang, P.T. Smoothened adopts multiple active and inactive conformations capable of trafficking to the primary cilium. PLoS ONE 4, e5182 (2009).
92. Wu, V.M., Chen, S.C., Arkin, M.R. & Reiter, J.F. Small molecule inhibitors of Smoothened ciliary localization and ciliogenesis. Proc. Natl. Acad. Sci. USA 109, 13644-13649 (2012).
93. Wang, Y. et al. Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS Chem. Biol. 7, 1040-1048 (2012).
94. Wang, Y. et al. Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chem. Biol. 19, 972-982 (2012).
95. Hassounah, N.B., Bunch, T.A. & McDermott, K.M. Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling. Clin. Cancer Res. 18, 2429-2435 (2012).
96. Kim, J. et al. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17, 388-399 (2010).
97. Kim, J. et al. Itraconazole and arsenic trioxide inhibit hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 23, 23-34 (2013).
98. Antonarakis, E.S. et al. Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 18, 163-173 (2013).
99. Ericson, J., Morton, S., Kawakami, A., Roelink, H. & Jessell, T.M. Two critical periods of Sonic Hedgehog signaling required for the specification of motor neuron identity. Cell 87, 661-673 (1996).
100. Maun, H.R. et al. Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active site. J. Biol. Chem. 285, 26570-26580 (2010).
101. Petrova, E., Rios-Esteves, J., Ouerfelli, O., Glickman, J.F. & Resh, M.D. Inhibitors of Hedgehog acyltransferase block Sonic Hedgehog signaling. Nat. Chem. Biol. 9, 247-249 (2013).
102. Stanton, B.Z. et al. A small molecule that binds Hedgehog and blocks its signaling in human cells. Nat. Chem. Biol. 5, 154-156 (2009).
103. Dijkgraaf, G.J. et al. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res. 71, 435-444 (2011).
104. Buonamici, S. et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2, 51ra70 (2010).
105. Lauth, M., Bergstrom, A., Shimokawa, T. & Toftgard, R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA 104, 8455-8460 (2007).
106. Hyman, J.M. et al. Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade. Proc. Natl. Acad. Sci. USA 106, 14132-14137 (2009).
107. Kim, J., Lee, J.J., Kim, J., Gardner, D. & Beachy, P.A. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc. Natl. Acad. Sci. USA 107, 13432-13437 (2010).
108. Beauchamp, E.M. et al. Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway. J. Clin. Invest. 121, 148-160 (2011).
109. Yauch, R.L. et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 326, 572-574 (2009).
110. Tao, H. et al. Small molecule antagonists in distinct binding modes inhibit drug-resistant mutant of smoothened. Chem. Biol. 18, 432-437 (2011).
111. Atwood, S.X., Chang, A.L. & Oro, A.E. Hedgehog pathway inhibition and the race against tumor evolution. J. Cell Biol. 199, 193-197 (2012).
112. Chang, A.L. & Oro, A.E. Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma. Arch. Dermatol. 148, 1325-1325 (2012).
113. Atwood, S.X., Li, M., Lee, A., Tang, J.Y. & Oro, A.E. GLI activation by atypical protein kinase C ?/? regulates the growth of basal cell carcinomas. Nature 494, 484-488 (2013).
114. Park, K.S. et al. A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat. Med. 17, 1504-1508 (2011).
115. Feldmann, G. et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196 (2007).
116. Richards, D.A. et al. A phase Ib trial of IPI-926, a hedgehog pathway inhibitor, plus gemcitabine in patients with metastatic pancreatic cancer. J. Clin. Oncol. 30 (suppl. 4), abstract 213 (2012).
117. Clement, V., Sanchez, P., de Tribolet, N., Radovanovic, I. & Ruiz i Altaba, A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol. 17, 165-172 (2007).
118. Ferruzzi, P. et al. In vitro and in vivo characterization of a novel Hedgehog signaling antagonist in human glioblastoma cell lines. Int. J. Cancer 131, E33-E44 (2012).
119. Domingo-Domenech, J. et al. Suppression of acquired docetaxel resistance in pProstate cancer through depletion of Notch-and Hedgehog-dependent tumor-initiating cells. Cancer Cell 22, 373-388 (2012).
120. Ramaswamy, B. et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway. Cancer Res. 72, 5048-5059 (2012).
121. Gruber-Olipitz, M. et al. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat. Med. advance online publication, doi:10.1038/nm.3328 (29 September 2013).
122. Schnidar, H. et al. Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. Cancer Res. 69, 1284-1292 (2009).
123. Mangelberger, D., Kern, D., Loipetzberger, A., Eberl, M. & Aberger, F. Cooperative Hedgehog-EGFR signaling. Front. Biosci. (Landmark Ed.) 17, 90-99 (2012).
124. Eimer, S. et al. Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures. Neuro-oncol. 14, 1441-1451 (2012).
125. Stecca, B. et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc. Natl. Acad. Sci. USA 104, 5895-5900 (2007).
126. Gurney, J.G., Severson, R.K., Davis, S. & Robison, L.L. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 75, 2186-2195 (1995).
127. CBTRUS, Central Brain Tumor Registry of the United States. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2008. ?http://www.cbtrus.org/2012-NPCR-SEER/CBTRUS- Report-2004-2008-3-23-2012.pdf? (2012).
128. McNeil, D.E., Cote, T.R., Clegg, L. & Rorke, L.B. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. Med. Pediatr. Oncol. 39, 190-194 (2002).
129. Cohen, D. et al. Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study. J. Clin Oncol. 31 (suppl.), abstract 4011 (2013).
130. Huff C.A.,et al. A phase I study of an oral Hedgehog pathway antagonist, BMS-833923, in patients with relapsed or refractory multiple myeloma. 53rd ASH Annual Meeting and Exposition abstract 3993 https://ash.confex.com/ash/2011/ webprogram/Paper44725.html? (2011).